Coastline Trust Co Decreases Stock Holdings in Johnson & Johnson $JNJ

Coastline Trust Co lessened its stake in Johnson & Johnson (NYSE:JNJ) by 20.8% in the 3rd quarter, HoldingsChannel reports. The fund owned 8,290 shares of the company’s stock after selling 2,182 shares during the quarter. Coastline Trust Co’s holdings in Johnson & Johnson were worth $2,195,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JNJ. QRG Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 5.7% in the 2nd quarter. QRG Capital Management Inc. now owns 440,815 shares of the company’s stock valued at $111,954,000 after purchasing an additional 23,837 shares during the last quarter. Security National Bank of Sioux City Iowa IA increased its holdings in Johnson & Johnson by 27.2% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 18,143 shares of the company’s stock valued at $4,608,000 after purchasing an additional 3,878 shares during the last quarter. Reynders McVeigh Capital Management LLC grew its position in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 76,513 shares of the company’s stock worth $19,432,000 after buying an additional 499 shares during the period. Bullseye Investment Management LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $63,000. Finally, Talon Private Wealth LLC raised its position in shares of Johnson & Johnson by 89.5% in the 2nd quarter. Talon Private Wealth LLC now owns 10,588 shares of the company’s stock valued at $2,689,000 after acquiring an additional 5,002 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Bank of America raised its price target for JNJ to $278 from $263, citing stronger expectations for Icotyde, Johnson & Johnson’s oral psoriasis treatment. The analyst now estimates the drug could generate up to $4.5 billion in peak sales, significantly above the prior $2.4 billion forecast. Icotyde sales estimate and price-target increase
• Positive Sentiment: New IMAAVY data showed sustained disease control and reduced corticosteroid reliance among adolescents with generalized myasthenia gravis, with no new safety signals. The findings support the growth potential of J&J’s pharmaceutical pipeline. IMAAVY generalized myasthenia gravis data
• Neutral Sentiment: JPMorgan reportedly expects JNJ’s stock to rise, while other coverage highlights the company’s strong economic moat, defensive business mix and long record of dividend increases. These factors may support the shares over the long term, but do not provide a major new near-term catalyst. JPMorgan analyst outlook
• Neutral Sentiment: A global J&J survey found that most women do not associate eye-health changes with menopause. The announcement raises awareness of an eye-health issue but appears unlikely to materially affect near-term revenue or earnings. Global eye-health and menopause survey
• Negative Sentiment: Investors are awaiting JNJ’s October 13 third-quarter earnings report, with one preview calling for roughly in-line revenue but an earnings miss. Another analyst report projected earnings about 12% below the consensus estimate, increasing caution ahead of the release. Johnson & Johnson third-quarter earnings preview
• Negative Sentiment: JNJ has risen sharply over the past year and is trading near its record high, leaving less room for disappointment. Profit-taking and valuation concerns may be weighing on the shares while investors assess patent-cliff risks, including STELARA biosimilar erosion.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 87,569 shares of company stock valued at $23,064,544. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ traded down $5.44 on Thursday, hitting $259.30. 2,178,303 shares of the stock were exchanged, compared to its average volume of 7,947,242. Johnson & Johnson has a 52 week low of $182.94 and a 52 week high of $281.07. The company has a market capitalization of $624.90 billion, a PE ratio of 30.02, a P/E/G ratio of 2.55 and a beta of 0.24. The business’s fifty day moving average is $266.53 and its 200 day moving average is $248.19. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the previous year, the business earned $2.77 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 62.11%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. TD Cowen boosted their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a report on Monday, July 13th. Guggenheim lifted their price target on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $275.87.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.